廣告
香港股市 已收市

  • 恒指

    18,089.93
    +17.03 (+0.09%)
     

  • 國指

    6,477.24
    +12.75 (+0.20%)
     

  • 上證綜指

    2,972.53
    +22.53 (+0.76%)
     

  • 道指

    38,956.85
    -155.31 (-0.40%)
     

  • 標普 500

    5,465.94
    -3.36 (-0.06%)
     

  • 納指

    17,768.68
    +51.03 (+0.29%)
     

  • Vix指數

    12.91
    +0.07 (+0.55%)
     

  • 富時100

    8,221.06
    -26.73 (-0.32%)
     

  • 紐約期油

    81.02
    +0.19 (+0.24%)
     

  • 金價

    2,309.20
    -21.60 (-0.93%)
     

  • 美元

    7.8087
    +0.0001 (+0.00%)
     

  • 人民幣

    0.9302
    +0.0006 (+0.06%)
     

  • 日圓

    0.0484
    -0.0002 (-0.49%)
     

  • 歐元

    8.3415
    -0.0238 (-0.28%)
     

  • Bitcoin

    61,891.57
    +480.13 (+0.78%)
     

  • CMC Crypto 200

    1,281.28
    -2.50 (-0.20%)
     

Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock

Zacks Equity Research
·2 分鐘文章

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals.

Many investors also have a go-to methodology that helps guide their buy and sell decisions. One way to find winning stocks based on your preferred way of investing is to use the Zacks Style Scores, which are indicators that rate stocks based on three widely-followed investing types: value, growth, and momentum.

Why Investors Should Pay Attention to This Value Stock

Finding good stocks at good prices, and discovering which companies are trading under their true value, are what value investors like to focus on. So, the Value Style Score takes into account ratios like P/E, PEG, Price/Sales, and Price/Cash Flow to highlight the most attractive and discounted stocks.

廣告

Halozyme Therapeutics (HALO)

San Diego, CA-based Halozyme Therapeutics is a biopharmaceutical company, focused on the development and commercialization of novel treatments for oncology indications by targeting tumor microenvironment. The company also licenses its novel drug delivery technology, ENHANZE, for subcutaneous (SC) administration of drugs.

HALO sits at a Zacks Rank #3 (Hold), holds a Value Style Score of B, and has a VGM Score of A. Compared to the Medical - Biomedical and Genetics industry's P/E of 23.7X, shares of Halozyme Therapeutics are trading at a forward P/E of 12.7X. HALO also has a PEG Ratio of 0.5, a Price/Cash Flow ratio of 15.6X, and a Price/Sales ratio of 7.3X.

Many value investors pay close attention to a company's earnings as well. For HALO, three analysts revised their earnings estimate upwards in the last 60 days, and the Zacks Consensus Estimate has increased $0.22 to $3.90 per share for 2024. Per share HALO boasts an average earnings surprise of 9.4%.

With strong valuation and earnings metrics, a good Zacks Rank, and top-tier Value and VGM Style Scores, investors should strongly think about adding HALO to their portfolios.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Halozyme Therapeutics, Inc. (HALO) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research